HomeCompareMNBEY vs PFE

MNBEY vs PFE: Dividend Comparison 2026

MNBEY yields 1.44% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MNBEY wins by $16.81M in total portfolio value
10 years
MNBEY
MNBEY
● Live price
1.44%
Share price
$38.18
Annual div
$0.55
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16.86M
Annual income
$14,872,629.28
Full MNBEY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MNBEY vs PFE

📍 MNBEY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNBEYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNBEY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNBEY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNBEY
Annual income on $10K today (after 15% tax)
$122.45/yr
After 10yr DRIP, annual income (after tax)
$12,641,734.89/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MNBEY beats the other by $12,619,414.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNBEY + PFE for your $10,000?

MNBEY: 50%PFE: 50%
100% PFE50/50100% MNBEY
Portfolio after 10yr
$8.45M
Annual income
$7,449,444.00/yr
Blended yield
88.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MNBEY
No analyst data
Altman Z
134.8
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNBEY buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNBEYPFE
Forward yield1.44%6.13%
Annual dividend / share$0.55$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$16.86M$49.6K
Annual income after 10y$14,872,629.28$26,258.71
Total dividends collected$16.68M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MNBEY vs PFE ($10,000, DRIP)

YearMNBEY PortfolioMNBEY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,988$288.11$9,153$693.39+$1.8KMNBEY
2$12,349$591.73$8,593$849.25+$3.8KMNBEY
3$14,456$1,243.03$8,336$1,066.78+$6.1KMNBEY
4$18,188$2,719.93$8,437$1,384.80+$9.8KMNBEY
5$25,858$6,396.39$9,013$1,875.40+$16.8KMNBEY
6$44,665$16,997.36$10,306$2,680.72+$34.4KMNBEY
7$102,671$54,878.82$12,820$4,101.38+$89.9KMNBEY
8$345,649$235,790.87$17,673$6,826.70+$328.0KMNBEY
9$1,853,596$1,483,751.81$27,543$12,591.86+$1.83MMNBEY
10$16,855,977$14,872,629.28$49,560$26,258.71+$16.81MMNBEY

MNBEY vs PFE: Complete Analysis 2026

MNBEYStock

MinebeaMitsumi Inc. manufactures and supplies machined components, and electronic devices and components in Japan, Europe, the United States, Asia, and internationally. It operates through four segments: Machined Components, Electronic Devices and Components, MITSUMI Business, and U-Shin business segment. The company offers bearing products, including miniature and small-sized ball bearings, rod end and spherical bearings, roller bearings, bushings, precision machined parts for aircraft, and medium- and large-sized ball bearings for aerospace use. It also provides bearing-related products, such as pivot assemblies and precision mechanical assemblies; and fasteners, defense related special components, and electromagnetic clutches and brakes. In addition, the company offers rotary components comprising fan motors, blowers, hybrid type stepping motors, PM stepping motors, small diameter/high speed PM stepping motors, brush DC motors, small brushless motors, power brushless motors, polygon mirror scanner motors, HDD spindle motors, high-pressure blowers, rotation angle sensors, fan units, and FDB motors. Further, it provides lighting devices for LCDs; resonant devices; and measuring components comprising strain gauges, force sensors, load cells, pressure gauges, torque transducers, vector sensors, digital indicators, and tensile and compression testing machines; sensors and sensor related products; coils, switches, and connectors; frequency and optical devices, power supply components, industrial machinery components, home security products, automotive components, and semiconductors. It offers its products for use in PCs and peripheral equipment, information and telecommunications equipment, household electrical appliances, automobiles, and aircraft parts. The company was formerly known as Minebea Co., Ltd. and changed its name to MinebeaMitsumi Inc. in January 2017. MinebeaMitsumi Inc. was incorporated in 1951 and is headquartered in Tokyo, Japan.

Full MNBEY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MNBEY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNBEY vs SCHDMNBEY vs JEPIMNBEY vs OMNBEY vs KOMNBEY vs MAINMNBEY vs JNJMNBEY vs MRKMNBEY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.